<p>，/PRNewswire/ -- DJS 法律集團宣佈正在代表 Hims &amp; Hers Health, Inc.（&#34;Hims &amp; Hers&#34;或&#34;公司&#34;）（紐約證券交易所代碼：HIMS）的投資者調查索賠，涉及證券法的違反。</p>
<p><strong>調查詳情：</strong> 本次調查的重點是公司是否發佈了誤導性聲明和/或未能披露與投資者相關的信息。諾和諾德於 2025 年 6 月 23 日發佈了一份新聞稿，宣佈由於對其非法大規模配製和欺騙性營銷的擔憂，終止與 Hims &amp; Hers Health, Inc.的&#34;合作&#34;。根據新聞稿，&#34;FDA 解決了 Wegovy®的短缺問題，基於其結論，諾和諾德完全滿足當前和預計的全國需求。為了支持患者從仿製的配製版本過渡到正品、FDA 批准的 Wegovy®，諾和諾德開始與遠程醫療公司合作。在合作一個多月後，Hims &amp; Hers Health, Inc.未能遵守法律，禁止以'個性化'的虛假幌子進行大規模銷售配製藥物，並傳播了危及患者安全的欺騙性營銷。&#34;基於此，Hims &amp; Hers 的股票在 2025 年 6 月 23 日下午交易中下跌了 31.7%。</p>
<p>如果您是遭受損失的股東，請聯繫我們參與。</p>
<p><strong>為什麼選擇 DJS 法律集團？</strong> DJS 法律集團的主要關注點是通過平衡的諮詢和積極的倡導來提高投資者回報。我們專注於證券集體訴訟、公司治理訴訟以及國內/國際併購評估。我們的客户是全球一些最大和最複雜的對沖基金和另類資產管理公司。我們客户的訴訟索賠是極其有價值的資產，值得尊重、關注和結果。</p>
<p>在某些司法管轄區，根據適用法律和倫理規則，本新聞稿可能被視為律師廣告。</p>
<p><strong>聯繫方式：</strong></p>
<p>David J. Schwartz</p>
<p>DJS 法律集團</p>
<p>274 White Plains Road, Suite 1</p>
<p>Eastchester, NY 10709</p>
<p>電話：914-206-9742</p>
<p>電子郵件：[email protected]</p>
<p>來源：DJS 法律集團 LLP</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwNzI4Jk5ld3NJdGVtSWQ9TEEzODM5MSZUcmFuc21pc3Npb25fSWQ9MjAyNTA3MjgxMDM0UFJfTkVXU19VU1BSX19fX19MQTM4Mzkx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwNzI4Jk5ld3NJdGVtSWQ9TEEzODM5MSZUcmFuc21pc3Npb25fSWQ9MjAyNTA3MjgxMDM0UFJfTkVXU19VU1BSX19fX19MQTM4Mzkx"/></p>

HIMS

<p>DJS Law Group 正在調查 Hims & Hers Health, Inc.是否存在潛在的證券欺詐違規行為，重點關注誤導性陳述和未披露的信息。此次調查是在 Novo Nordisk 因對 Hims & Hers 的非法大規模配藥和欺騙性營銷行為的擔憂而終止與其合作後進行的。這導致 Hims & Hers 的股價大幅下跌 31.7%。遭受損失的股東被鼓勵聯繫 DJS Law Group 以參與調查</p>

<p>, /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Hims &amp; Hers Health, Inc. (&#34;Hims &amp; Hers&#34; or &#34;the Company&#34;) (NYSE: HIMS) for violations of the securities laws.</p>
<div class="lb-trans"><p>，/PRNewswire/ -- DJS 法律集團宣佈正在代表 Hims &amp; Hers Health, Inc.（&#34;Hims &amp; Hers&#34;或&#34;公司&#34;）（紐約證券交易所代碼：HIMS）的投資者調查索賠，涉及證券法的違反。</p>
</div><p><strong>INVESTIGATION DETAILS:</strong> The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. Novo Nordisk issued a press release on June 23, 2025, announced that it was terminating its &#34;collaboration with Hims &amp; Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing.&#34; According to the press release, &#34;the FDA resolved the Wegovy® shortage based on its conclusion that Novo Nordisk is fully meeting current and projected nationwide demand for this medicine. In support of transitioning patients from knock-off compounded versions to authentic, FDA-approved Wegovy® through NovoCare® Pharmacy, Novo Nordisk began collaborating with telehealth companies. Over one month into the collaboration, Hims &amp; Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk.&#34; Based on this, shares of Hims &amp; Hers fell by 31.7% in afternoon trading on June 23, 2025.</p>
<div class="lb-trans"><p><strong>調查詳情：</strong> 本次調查的重點是公司是否發佈了誤導性聲明和/或未能披露與投資者相關的信息。諾和諾德於 2025 年 6 月 23 日發佈了一份新聞稿，宣佈由於對其非法大規模配製和欺騙性營銷的擔憂，終止與 Hims &amp; Hers Health, Inc.的&#34;合作&#34;。根據新聞稿，&#34;FDA 解決了 Wegovy®的短缺問題，基於其結論，諾和諾德完全滿足當前和預計的全國需求。為了支持患者從仿製的配製版本過渡到正品、FDA 批准的 Wegovy®，諾和諾德開始與遠程醫療公司合作。在合作一個多月後，Hims &amp; Hers Health, Inc.未能遵守法律，禁止以'個性化'的虛假幌子進行大規模銷售配製藥物，並傳播了危及患者安全的欺騙性營銷。&#34;基於此，Hims &amp; Hers 的股票在 2025 年 6 月 23 日下午交易中下跌了 31.7%。</p>
</div><p>If you are a shareholder who suffered a loss, contact us to participate.</p>
<div class="lb-trans"><p>如果您是遭受損失的股東，請聯繫我們參與。</p>
</div><p><strong>WHY DJS LAW GROUP?</strong> DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&amp;A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.</p>
<div class="lb-trans"><p><strong>為什麼選擇 DJS 法律集團？</strong> DJS 法律集團的主要關注點是通過平衡的諮詢和積極的倡導來提高投資者回報。我們專注於證券集體訴訟、公司治理訴訟以及國內/國際併購評估。我們的客户是全球一些最大和最複雜的對沖基金和另類資產管理公司。我們客户的訴訟索賠是極其有價值的資產，值得尊重、關注和結果。</p>
</div><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.</p>
<div class="lb-trans"><p>在某些司法管轄區，根據適用法律和倫理規則，本新聞稿可能被視為律師廣告。</p>
</div><p><strong>CONTACT:</strong></p>
<div class="lb-trans"><p><strong>聯繫方式：</strong></p>
</div><p>David J. Schwartz</p>
<div class="lb-trans"><p>David J. Schwartz</p>
</div><p>DJS Law Group</p>
<div class="lb-trans"><p>DJS 法律集團</p>
</div><p>274 White Plains Road, Suite 1</p>
<div class="lb-trans"><p>274 White Plains Road, Suite 1</p>
</div><p>Eastchester, NY 10709</p>
<div class="lb-trans"><p>Eastchester, NY 10709</p>
</div><p>Phone: 914-206-9742</p>
<div class="lb-trans"><p>電話：914-206-9742</p>
</div><p>Email: [email protected]</p>
<div class="lb-trans"><p>電子郵件：[email protected]</p>
</div><p>SOURCE DJS Law Group LLP</p>
<div class="lb-trans"><p>來源：DJS 法律集團 LLP</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwNzI4Jk5ld3NJdGVtSWQ9TEEzODM5MSZUcmFuc21pc3Npb25fSWQ9MjAyNTA3MjgxMDM0UFJfTkVXU19VU1BSX19fX19MQTM4Mzkx" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LA38391&amp;Transmission_Id=202507281034PR_NEWS_USPR_____LA38391&amp;DateId=20250728"/></p>

Hims & Hers Health, Inc.因涉嫌證券欺詐違規行為被調查 - 請聯繫 DJS 律師事務所以討論您的權利 - HIMS